JPMorgan Reduces Stake in Evotec SE, Goldman Sachs Increases Holdings
EVO is trading near its 52-week low of $2.84 (12% above the low).
Summary
JPMorgan Chase & Co. significantly reduced its total voting rights in Evotec SE from 5.62% to 3.64%, while The Goldman Sachs Group, Inc. increased its stake from 4.63% to 5.27%.
Key Events · Ownership and Investor Activity · EVO
-
JPMorgan Reduces Stake
JPMorgan Chase & Co. decreased its total voting rights in Evotec SE from 5.62% to 3.64%, crossing the 3% threshold on December 24, 2025. This reduction represents approximately $11.2 million in shares.
-
Goldman Sachs Increases Holdings
The Goldman Sachs Group, Inc. increased its total voting rights in Evotec SE from 4.63% to 5.27%, crossing the 5% threshold on December 23, 2025. This increase represents approximately $3.6 million in shares.
-
Institutional Rebalancing
The changes reflect significant adjustments in the positions of two major financial institutions, indicating a shift in their investment strategies regarding Evotec SE.
Analysis · EVO · Life Sciences
This 6-K filing indicates notable shifts in institutional ownership for Evotec SE. JPMorgan Chase & Co.'s reduction of its total voting rights by nearly 2 percentage points, representing approximately $11.2 million in shares, suggests a re-evaluation of its position. Conversely, Goldman Sachs's increase in its total holdings, though smaller in magnitude, shows continued interest. While institutional rebalancing is common, a significant reduction by a major financial institution like JPMorgan could be interpreted as a cautious signal, potentially outweighing the smaller increase by Goldman Sachs. Investors should monitor future institutional filings for further trends.
How filings like this one have moved
In the 30 days to Sep 15, 2026, 29.9% of the 1678 measured filings Wiseek scored 7 moved their stock by 5% or more by the next session's close. The median move was -0.25%. These are measured outcomes after filings of this importance, not a forecast for this one.
Measured one observation per ticker per day, after exclusions. Current figures: Filing Impact Tracker · open dataset
At the time of this filing, EVO was trading at $3.18 on NASDAQ in the Life Sciences sector, with a market capitalization of approximately $1.1B. The 52-week trading range was $2.84 to $4.80. This filing was assessed with neutral market sentiment and an importance score of 7 out of 10.